Jordi Rodon Ahnert, MD, PhD
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
About Dr. Rodon Ahnert
Dr. Jordi Rodón specializes in early drug development, biomarker discovery, personalized cancer medicine, and neuro-oncology. He received his medical and doctoral degrees from the Universitat Autonoma de Barcelona, and pursued post-graduate medical training at the Vall d’Hebron University Hospital. Dr. Rodón spent two years at the Advanced Drug Development program at the Institute for Drug Development (IDD) in San Antonio, Texas, and completed his training in drug development in ICT as a senior clinical research fellow. He joined the MD Anderson faculty in 2016 as an Associate Professor in the Department of Investigational Cancer Therapeutics (ICT) with a joint appointment in the Department of Genomic Medicine. Dr. Rodón also serve s as Associate Medical Director for the Institute for Personalized Cancer Therapy and Clinical Co-Director of the Precision Oncology Decision Support Group. Over the course of his career, Dr. Rodón has been the principal or co-principal investigator on over 30 early phase clinical trials focusing on a range of advanced solid malignancies, partnering with leaders in industry including Novartis, Merck, Eli Lilly, Genentech, Sanofi, and others. With this, he has contributed to about 60 peer-reviewed publications detailing both trial results and basic research findings. Dr. Rodón’s most significant contributions to the field include the development of PI3K, FGFR and TGFbeta inhibitors and multiple translational collaborations in those fields.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Medical Director, Department of Institute for Personalized Cancer Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | Universitat Autonoma de Barcelona, Barcelona, ESP, PHD, Medicine |
| 2008 | Universitat de Barcelona, Barcelona, ESP, MS, Experimental Medicine |
| 2005 | Institut Català d'Oncologia, Barcelona, ESP, MD, Clinical Residency, Medical Oncology |
| 2000 | Universitat Autonoma de Barcelona, Barcelona, ESP, MD, Medicine |
Postgraduate Training
| 2018-2018 | Postgraduate Training, 31st Annual Pharmacokinetics for Pharmaceutical Scientists, University of California, School of Pharmacy, San Francisco, CA |
| 2013-2013 | Postgraduate Training, Pharmacokinetics: a comprehensive overview of Principles and applications, Barnett Educational Services, Philadelphia, PA |
| 2007-2008 | Clinical Internship, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2005-2007 | Clinical Fellowship, Advanced Oncology Drug Development, The Institute for Drug Development, Cancer Therapy and Research Center, and the University of Texas, San Antonio, TX |
Board Certifications
| 2008 | Board Certified in Medical Oncology by the Spanish Health Ministry |
| 2007 | ECFMG Certification (USMLE Exams) |
Experience & Service
Academic Appointments
Clinical Co-Director, Department of Precision Oncology Decision Support Team, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Co-chair, Clinical Trials Task Force, Cancer Core Europe, Paris, 2014 - 2018
Administrative Appointments/Responsibilities
Associate Medical Director, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Clinical Co-Director, Department of Precision Oncology Decision Support Team, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Honors & Awards
| 2016 | Best mentor award, ECCO-AACR-EORTC-ESMO Methods in Clinical Cancer Research (MCCR) Workshop, Methods in Clinical Cancer Research (MCCR), Course Number: Edition 18 |
| 2014 | Finalist HINNOVAR Award, Esade/Novartis |
| 2010 | Award Mejores Ideas (Best Ideas Award), Diario Medico |
| 2007 | Scholar-in-Training Award, AACR-Aflac, Inc |
| 2006 | Oppenheimer Fellow in Drug Development, Cancer Therapy and Research Center |
Selected Publications
Peer-Reviewed Articles
- Harding JJ, Bauer TM, Tan DSW, Bedard PL, Rodon J, Doi T, Schnell C, Iyer V, Baffert F, Radhakrishnan R, Fabre C, Juric D. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Invest New Drugs 37(2):271-281, 2019. e-Pub 2018. PMID: 30073466.
- Sankhala K, Takimoto CH, Mita AC, Xiong H, Rodón J, Mehrvarz Sarshekeh A, Burns K, Iizuka K, Kopetz S. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Invest New Drugs 37(1):76-86, 2019. e-Pub 2018. PMID: 29667134.
- Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. Identification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma. Mol Cell Proteomics 17(11):2132-2145, 2018. e-Pub 2018. PMID: 30072578.
- Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, Fassò M, Osborne S, Molinero L, O'Hear C, Grossman W, Baehring J. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol 140(2):317-328, 2018. e-Pub 2018. PMID: 30073642.
- Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J. First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol 29(9):1911-1917, 2018. e-Pub 2018. PMID: 30060061.
- Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanovic N, Cmiljanovic V, Stumm M, Dimitrijevic S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 96:6-16, 2018. e-Pub 2018. PMID: 29660598.
- Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol 82(2):285-298. e-Pub 2018. PMID: 29882016.
- Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM, Shapiro GI. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist 23(4):401-e38, 2018. e-Pub 2018. PMID: 29593099.
- Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, Dienstmann R, Gonzalez-Perez A, Lopez-Bigas N. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med 10(1):25, 2018. e-Pub 2018. PMID: 29592813.
- Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol 36(13):1291-1299, 2018. PMID: 29401002.
- Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 7691(554):189-194, 2018. e-Pub 2018. PMID: 29420467.
- Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 30035249.
- Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V,. A First-in-Human Phase I Study of SAR125844, A Selective MET Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Tumors with MET Amplification. European Journal of Cancer(87):131-139, 2017. PMID: 29145039.
- Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L,. Hepatic Safety Analysis of Trabectedin: Results of a Pharmacokinetic Study With Trabectedin in Patients with Hepatic Impairment and Experience From a Phase 3 Clinical Trial. Investigative New Drugs 36(3):476-486, 2017. PMID: 29177975.
- Dienstmann R, Rodon J, Tabernero J. Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test. Mol Oncol 9(5):940-50, 2015. e-Pub 2014. PMID: 25081646.
- de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 12(4):197-212, 2015. e-Pub 2014. PMID: 25421275.
- Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 33(2):357-70, 2015. e-Pub 2014. PMID: 25529192.
- Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 27(4):533-46, 2015. PMID: 25873175.
- Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 7(283):283ra51, 2015. PMID: 25877889.
- Rodon J, Carducci MA, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res 21(3):553-60, 2015. e-Pub 2014. PMID: 25424852.
- Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodon J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res 21(3):585-93, 2015. e-Pub 2014. PMID: 25473003.
- Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group. Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med 19(103):101-8, 2015. PMID: 25725224.
- Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group. Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med 19(103):109-16, 2015. PMID: 25725225.
- Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortés J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 5:8179, 2015. e-Pub 2015. PMID: 25670223.
- Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer 112(4):650-9, 2015. e-Pub 2015. PMID: 25625276.
- Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group. Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med 18(101):323-30, 2014. PMID: 25549703.
- Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med 18(101):331-9, 2014. PMID: 25549704.
- Bellmunt J, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist 19(9):917-8, 2014. e-Pub 2014. PMID: 25142843.
- Rodon J, Braña I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 32(4):670-81, 2014. e-Pub 2014. PMID: 24652201.
- Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, Benjamin D, Ketchum N, Michalek J, Tolcher A, Wright J, Sarantopoulos J. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol 74(1):77-84, 2014. e-Pub 2014. PMID: 24817603.
- Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 13(5):1021-31, 2014. e-Pub 2014. PMID: 24748656.
- Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon J, Miles CP, Yingling JM, Lahn MM. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol 77(5):796-807, 2014. PMID: 24868575.
- Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20(7):1900-9, 2014. e-Pub 2014. PMID: 24523439.
- Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience 1(10):614-23, 2014. e-Pub 2014. PMID: 25593991.
Invited Articles
- Hierro C, Alsina M, Sánchez M, Serra V, b|Rodon J, Tabernero J. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. Ann Oncol 29(7):1605, 2018. PMID: 29300805.
- Kurnit KC, Ileana Dumbrava EE, Litzenburger BC, Khotskaya YB, Johnson A, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey A, Sánchez N, Holla VR, Mendelsohn J, Shaw KRM, Bernstam EV, Mills GB, Meric-Bernstam F. PRECISION ONCOLOGY DECISION SUPPORT: CURRENT APPROACHES AND STRATEGIES FOR THE FUTURE. Clin Cancer Res, 2018. PMID: 29420224.
- Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Ann Oncology 1(29):30-35, 2018. PMID: 29140430.
Editorials
- Subbiah V, Rodon J, Yap TA. Precision oncology: East meets West. Int J Cancer 9(142):1734-1737, 2018. PMID: 29243227.
- Yap TA, Rodon J. Development of Molecularly Driven Targeted Combination Strategies. Oncologist 12(22):1421-1423, 2017. PMID: 29038233.
- Rodon J. An (only) partially established paradigm of drug development of targeted therapies. Eur J Cancer 50(12):2037-9, 2014. PMID: 24908539.
Abstracts
- Azaro A, Rodon J, Middleton MR, Baird RD, Herrmann R, Fielder U, Haunschild J, Häuptle M, Hermann FJ, Schreiner S, Harstrick A, Dawson KM, Omlin AG. First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors. 2018 ASCO Meeting, 2018.
- Merchan JR, Rodon JA, Falchook G, Ostertag D, Tejera D, Gruber HE, Jolly DJ, Shorr J. Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma. 2018 ASCO Meeting, 2018.
- Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F,Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Rodon Ahnert J, Tawbi HA, Welsh JW, Meric-Bernstam F, Hong DS. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. 2018 ASCO Meeting, 2018.
- Rodon JA, Taylor MH, O'Reilly EM, Zhang J, Doebele RC, Ben Y, Sharp LL, Boyle WJ, Chang C, Frey G, Chen W, Melnick M, Short JM, Burris HA. A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors. 2018 ASCO Meeting, 2018.
- Rodon J, Soria J-C, Berger R, Miller WH, Lazar V, Rubin E, Tsimberidou AM, Saintigny P, Ackerstein A, Brana I, Loriot Y, Afshar M, Miller VA, Wunder F, Bresson C, Martini J-F, Mendelsohn J, Schilsky RL, Lee JJ, Kurzrock R. WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. 2018 ASCO Meeting, 2018.
- Piha-Paul SA, Fu S, Hong DS, Janku F, Karp DD, Naing A, Pant S, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Yap TA, Meric-Bernstam F. Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. 2018 ASCO Meeting, 2018.
- Racca F, Hierro C, Moreno D, Vilaro M, Landolfi S, Vivancos A, Jimenez J, Macarulla T, Capdevila J, Elez E, Argiles G, Sauri T, Cruz C, Azaro A, Castro S, Nuciforo P, Rodon J, Tabernero J, Alsina M. Knocking on molecular alterations in advanced gastric cancer (AGC). J Clin Oncol, Abstracts of the 2015 ASCO Annual Meeting 33(15S), 2015.
- Ortiz C, Argiles G, Elez E, Matito J, Mendizabal L, Lo Giacco D, Mancuso FM, Sanz-Garcia E, Macarulla T, Alsina M, Capdevila J, Sauri T, Azaro A, Cruz C, Hierro C, Cajal SRY, Nuciforo P, Rodon J, Tabernero J, Vivancos A. Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program. J Clin Oncol, The 2015 ASCO Annual Meeting 33(15S), 2015.
- Kristeleit RS, Brown NF, F Hess D, Joerger M, Von Moos R, Rodon J, Hierro C, Childs A, Stathis A, Dimitrijevic S, Stumm M, Herrmann R, Sessa C, Bize V, Hess V, Wicki A. A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results. J Clin Oncol, The 2015 ASCO Annual Meeting 33(15S), 2015.
- Garrido-Castro AC, Argiles G, Moreno D, Vilaro M, Rodriguez-Freixinos V, Macarulla T, Cruz C, Azaro A, Elez E, Alsina M, Perez-Garcia JM, Jimenez J, Nuciforo P, Vivancos A, Seoane J, Del Campo JM, Rodon J, Tabernero J, Oaknin A. Early drug development in advanced gynecologic cancer based on genetic tumor profiling. J Clin Oncol, The 2015 ASCO Annual Meeting 33(15S), 2015.
- Sanz-Garcia E, Elez E, Argiles G, Hernandez-Losa J, Vivancos A, Moreno D, Macarulla T, Capdevila J, Alsina M, Sauri T, Hierro C, Azaro A, Zambrano CC, Vilaro M, Jimenez J, Landolfl S, Nuciforo P, Cajal SRY, Rodon J, Tabernero J. Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort. J Clin Oncol, Abstracts of the 2015 ASCO Gastrointestinal Cancers Symposium 33(3S), 2015.
- Azaro A, Marino D, Garrido-Castro A, Cruz C, Alsina M, Perez J, Dienstmann R, Argiles G, Hierro C, Berzosa M, Adamo B, Tabernero J, Rodon J. PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vail d'Hebron experience. Eur J Cancer, Abstracts of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 50(6S), 2014.
- Dienstmann R, Bahleda R, Adamo B, Rodon J, Varga A, Gazzah A, Platero S, Smit H, Perera T, Zhong B, Stuyckens K, Elsayed Y, Takimoto C, Peddareddigari V, Tabernero J, Luo FR, Soria JC. First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. Cancer Res, AACR Annual Meeting 74(19S), 2014.
- Elez Fernandez, ME, Argiles G, Matito J, Mendizabal L, Moreno D, Jimenez J, Hernandez-Losa J, Macarulla T, Capdevila J, Alsina M, Sauri T, Azaro A, Cruz Zambrano C, Landolfi S, Sanz E, Ramon y Cajal S, Nuciforo P, Rodon J, Tabernero J, Vivancos A. Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC). J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
- Garrido-Castro Ana C, Argiles G, Moreno D, Rodriguez-Freixinos, Vilaro M, Macarulla T, Curz Zambrano C, Azaro A, Adamo B, Alsina M, Jimenez J, Nuciforo P, Vivancos A, Meire A, Del Campo JM, Rodon J, Tabernero J, Oaknin A. Molecular profiling in gynecologic cancer and matched targeted therapy: a step toward improving personalized medicine. Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
Book Chapters
- Mulet-Margalef N, Miquel JM, Rodon J. Polymer-drug conjugates. In: Drug Delivery in Oncology, 56-73, 2014.
Patient Reviews
CV information above last modified August 19, 2024